| Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT | |
| Xuan Li; Wang Yu; Chen Jia; Jiang Erlie; Gao Li; Wu Bingyi; Deng Lan; Liang Xinquan; Huang Fen; Fan Zhiping | |
| 2019 | |
| 关键词 | FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia allogeneic hematopoietic stem cell transplantation relapse sorafenib |
| ISSN号 | 1523-6536 |
| DOI | 10.1016/j.bbmt.2019.04.018 |
| URL标识 | 查看原文 |
| 收录类别 | PUBMED |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6341861 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Xuan Li,Wang Yu,Chen Jia,et al. Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT[J],2019. |
| APA | Xuan Li.,Wang Yu.,Chen Jia.,Jiang Erlie.,Gao Li.,...&Liu Qifa.(2019).Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT.. |
| MLA | Xuan Li,et al."Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT".(2019). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论